Current filters:


Shire to spend $5.2 billion to buy NPS Pharma

Shire to spend $5.2 billion to buy NPS Pharma


Recently jilted Ireland-headquartered Shire says it is to acquire NPS Pharmaceuticals, confirming recent…

BiotechnologyEuropeGattexMergers & AcquisitionsNatparaNPS PharmaceuticalsRare diseasesRevestiveShire

New treatment offers hope for short-bowel syndrome patients


A new drug, teduglutide, offers significant relief for patients with short-bowel syndrome intestinal…

Gastro-intestinalsGattexNPS PharmaceuticalsPharmaceuticalResearchteduglutide

Unanimous FDA advisory panel backing for NPS Pharma's Gattex


The US Food and Drug Administration's Gastrointestinal Drugs Advisory Committee yesterday voted unanimously…

Gastro-intestinalsGattexNorth AmericaNPS PharmaceuticalsPharmaceuticalRegulationteduglutide

FDA posts briefing papers for review of NPS Pharma's Gattex for SBS


The USA Food and Drug Administration has posted briefing materials for the October 16 Gastrointestinal…

Gastro-intestinalsGattexNorth AmericaNPS PharmaceuticalsPharmaceuticalRegulation

NPS Pharma posts overall positive Gattex data, but shares plunge due to two deaths


Shares in USA-based NPS Pharmaceuticals (Nasdaq: NPSP) plummeted as much as 38% to $4.92 in morning trading…

Gastro-intestinalsGattexNPS PharmaceuticalsNycomedPharmaceuticalResearchRevestive

NPS Pharma soars as Gattex meets primary efficacy endpoint in Ph III study


Shares of US specialty drug developer NPS Pharmaceuticals (Nasdaq: NPSP) soared 22% to $9.30 in early…

Gastro-intestinalsGattexNPS PharmaceuticalsNycomedPharmaceuticalResearchteduglutide

Back to top